News from swedish orphan biovitrum ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 30, 2019, 02:17 ET Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by...


Aug 22, 2019, 02:15 ET Sobi has Entered Into Agreement to Sell Priority Review Voucher

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review...


Jul 17, 2019, 02:11 ET Sobi Publishes Report for Second Quarter 2019

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2019. Total revenue was SEK 3,163 M (2,289), with 38...


Jul 16, 2019, 03:15 ET Sobi Invites Entries to First Sobi Scientific Innovation Awards

Sobi™ has established the Sobi Scientific Innovation Awards, with a focus on the future of haemophilia care, to recognise innovation and scientific...


Jul 09, 2019, 02:20 ET Switching to Extended Half-life Prophylaxis Impacted Clinical Outcomes and Improved Quality of Life for People With Haemophilia A or B

Clinical study data on switching haemophilia A and B patients from on-demand treatment to extended half-life (EHL) prophylaxis showed a positive...


Jul 08, 2019, 07:18 ET Invitation - Presentation of Sobi's Q2 2019 Results

On 17 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2019. Financial analysts and...


Jul 08, 2019, 02:36 ET Interim Data Evaluating Elocta® for Immune Tolerance Induction in People With Inhibitors and Severe Haemophilia A Shared at ISTH 2019

Interim results from verITI-8, an ongoing prospective, phase 4 study evaluating the efficacy of Elocta® (efmoroctocog alfa), for first-time Immune...


Jul 08, 2019, 02:08 ET People With Haemophilia and Female Carriers in Sweden Have Higher Risk of Anxiety, Depression and Pain, Based on Treatment Patterns: Swedish Orphan Biovitrum

People with haemophilia have an increased risk of acute and chronic pain, and long-term disability, associated with bleeds. Anxiety and depression...


Jun 25, 2019, 08:03 ET Sobi Presents Study Data Supporting Increased Possibilities and Improved Clinical Outcomes for People With Haemophilia at ISTH

Sobi™ presents data at the ISTH 2019: The 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6 – 10 July ...


Jun 18, 2019, 03:18 ET New Data Demonstrates Impact of Emapalumab in Patients With Macrophage Activation Syndrome (MAS)

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces that new research demonstrating the effects of emapalumab in patients with macrophage ...


Jun 12, 2019, 07:30 ET Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology

Intended reorganisation of R&D to increase focus and investment in late-stage development Plans to establish centres of excellence in Sweden and...


Jun 12, 2019, 07:10 ET Sobi Acquires Emapalumab and Related Assets

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has signed an agreement to acquire, from Novimmune's shareholders, a newly established company...


May 10, 2019, 03:29 ET Individualised Extended Half-life Factor Replacement Therapy Controls Haemostasis in Orthopaedic Surgery

Today, Sobi™ and Sanofi will present data demonstrating that Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) can provide perioperative...


Apr 30, 2019, 07:20 ET Sobi™ Appoints Amy Pott as New Head of Sobi North America

Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Amy Pott as the new Head of Sobi North America. She takes over effective today, replacing...


Apr 25, 2019, 02:18 ET Sobi Publishes Report for First Quarter 2019

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the first quarter 2019. Total revenues were SEK 3,265 M (1,964), with 66...


Apr 18, 2019, 04:13 ET Sobi™ Publishes 2018 Annual and Sustainability Report

STOCKHOLM, April 18, 2019 /PRNewswire/ - Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company's 2018 Annual and Sustainability Report. ...


Apr 12, 2019, 04:25 ET Invitation - Presentation of Sobi's Q1 2019 Results

n 25 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial...


Mar 25, 2019, 04:19 ET Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)

Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards....


Feb 26, 2019, 03:29 ET New Emapalumab Data Presented at Transplantation and Cellular Therapy (TCT) Meeting Highlight Post-transplant Treatment Outcomes in Primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical...


Feb 21, 2019, 07:42 ET Invitation to Sobi Capital Markets Day 14 May 2019

Save the date for Swedish Orphan Biovitrum AB (publ) (Sobi™) Capital Markets Day on 14 May 2019. The event will take place at Karolinska Institutet...


Feb 11, 2019, 08:48 ET Invitation - Presentation of Sobi's Q4/FY 2018 Results

On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial ...


Feb 07, 2019, 03:21 ET Sobi Presents Comprehensive Study Data on Extended Half-life Haemophilia Treatments at EAHAD

Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic, 6-8 February...


Jan 24, 2019, 02:14 ET Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announced today that it has completed the acquisition from AstraZeneca of rights to Synagis®...


Dec 03, 2018, 21:49 ET Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in...


Dec 02, 2018, 08:54 ET At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years

Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, the most...